drugset
drugset / Trial / NCT02917304

A Study to Evaluate the Efficacy and Safety of GC3110A in Healthy Subjects Aged 65 Years and Older

NCT02917304 ↗

Phase 3 Completed 274 enrolled Green Cross Corporation
NaSingle-groupOpen-labelPrevention

Summary

The purpose of this study is to evaluate immunological efficacy and safety of GC3110A among healthy adults over 65 years of age.

Timeline

Start
2016-10-10
Primary completion
2016-12-02
Completion
2017-05-08

Drugs

EvaluationDrugModalityDoseRoute
Subject GC3110A Vaccine 0.5 ml Intramuscular

Indications

influenza